Edwards Lifesciences Corporation (EW)

NYQ – Real vaqt narxi. Valyuta: USD

79.73

+2.56 (3.32%)

Yopilishda: May 12, 2026, 4:00 PM EDT

13.05.2026

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

10.05.2026

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.

04.05.2026

Edwards Lifesciences Announces Appointment of CFO

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planni.

02.05.2026

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospectiv.

29.04.2026

Artisan Global Opportunities Fund Q1 2026 Portfolio Activity

During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox. In addition to Linde, Shopify and Amazon, we also added to Woodward and Spotify during the quarter. We ended our investment campaigns in Netflix, Snowflake and RELX during the quarter.

28.04.2026

Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences.

27.04.2026

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

23.04.2026

Edwards Lifesciences Reports First Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to.

30.03.2026

Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025). The new TRISCEND II trial data presented today during.

Edwards Lifesciences Corporation (EW)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Edwards Lifesciences Announces Appointment of CFO

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

Artisan Global Opportunities Fund Q1 2026 Portfolio Activity

Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Videolar

Press-relizlar

Edwards Lifesciences Announces Appointment of CFO

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

Edwards Lifesciences Reports First Quarter Results

Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Edwards Lifesciences Announces Appointment of CFO

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

Artisan Global Opportunities Fund Q1 2026 Portfolio Activity

Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Videolar

Press-relizlar

Edwards Lifesciences Announces Appointment of CFO

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

Edwards Lifesciences Reports First Quarter Results

Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

Search stocks

Edwards Lifesciences Corporation (EW)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Edwards Lifesciences Announces Appointment of CFO

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

Artisan Global Opportunities Fund Q1 2026 Portfolio Activity

Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Videolar

Press-relizlar

Edwards Lifesciences Announces Appointment of CFO

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

Edwards Lifesciences Reports First Quarter Results

Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

Edwards Lifesciences Announces Appointment of CFO

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

Artisan Global Opportunities Fund Q1 2026 Portfolio Activity

Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Videolar

Press-relizlar

Edwards Lifesciences Announces Appointment of CFO

Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue

Edwards Lifesciences Reports First Quarter Results

Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits